A-23 | Impact of SGLT-2 Inhibitors on intra-hospital length of stay after Acute Myocardial Infarction in Patients with Type II Diabetes Mellitus treated with PCI

Type 2 diabetes mellitus (T2DM) is one of the most serious causes of cardiovascular disease. Recent clinical studies have shown a reduction of adverse cardiovascular outcomes in patients with T2DM treated with SGLT2i (sodium-glucose co-transporter 2 inhibitor). Nevertheless, there are limited studies that have assessed the impact of prior use of SGLT2i to non-SGLT2i on length of stay for patients that underwent percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). This retrospective cohort study identified 7653 patients with T2DM being treated with an SGLT2i presenting with AMI that underwent PCI between 2020 and 2022. The primary outcome was defined as length of stay after PCI. Negative binomial regression was used to determine the association between home SGLT2i use and length of stay following PCI. Of the 7653 patients, 687 (8.98%) were on an SGLT2i at home and 6966 (91.02%) non-SGLT2i patients. Through negative binomial regression, we found SGLT2i use is significantly and inversely associated with length of stay, such that not taking an SGLT2 inhibitor at home increases the count of days by a factor of 1.109 compared to patients taking an SGLT2 inhibitor at home (χ2 = 11.24, p < 0.001, 95% CI [0.849, 0.958]). In conclusion, patients that had been previously taking an SGLT2i at home that presented with ACS and underwent subsequent PCI, had a decreased length of stay in comparison to those that had not been taking an SGLT2i. Our findings suggest yet another potential benefit of treating patients suffering from T2DM with an SGLT2i.